This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Medipost Co., Ltd. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: The Innovative Contributions of Dong Hyon Kim
Introduction
Dong Hyon Kim is a notable inventor based in Seongnam-si, South Korea. He has made significant strides in the field of pharmaceuticals, particularly in the treatment of inflammatory diseases. His work focuses on utilizing mesenchymal stem cells to develop effective therapeutic solutions.
Latest Patents
Dong Hyon Kim holds a patent for a pharmaceutical composition comprising mesenchymal stem cells as an effective ingredient for the prevention or treatment of inflammatory diseases. This innovative composition includes HLA-A2-expressing mesenchymal stem cells, which have been shown to inhibit the secretion of the inflammatory cytokine TNF-a. Additionally, these stem cells increase the expression of anti-inflammatory markers such as CD163 and Arg-1. This patent highlights the potential of using mesenchymal stem cells to suppress inflammation and treat various inflammatory conditions.
Career Highlights
Dong Hyon Kim is associated with Medipost Co., Ltd., a company that focuses on developing innovative stem cell therapies. His work at Medipost has been instrumental in advancing the understanding and application of stem cell technology in medicine. With a patent portfolio that includes 1 patent, he continues to contribute to the field of regenerative medicine.
Collaborations
Dong Hyon Kim has collaborated with notable colleagues, including Yun Sun Yang and Wonil Oh. These partnerships have fostered a collaborative environment that enhances research and development efforts in the field of stem cell therapy.
Conclusion
Dong Hyon Kim's contributions to the field of pharmaceuticals, particularly through his innovative patent on mesenchymal stem cells, demonstrate his commitment to advancing medical science. His work has the potential to significantly impact the treatment of inflammatory diseases, showcasing the importance of innovation in healthcare.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile